|
|
|
| Investigation of the molecular mechanism of Yiqi Huatan Prescription in the treatment of coronavirus disease 2019 based on network pharmacology |
| CHEN Xueqing1 LIU Yanzhui2 FENG Jing3 LUO Yuanyuan4 LI Shan5 |
1.Department of Clinical Laboratory, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510040, China;
2.Department of Clinical Laboratory, People’s Hospital of Suixi County, Zhanjiang City, Guangdong Province, Suixi 524300, China;
3.Department of Respiratory Medicine, Zhengzhou Yihe Hospital Affiliated to He’nan University, He’nan Province, Zhengzhou 450046, China;
4.Department of Critical Care Medicine, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510040, China;
5.Department of Pathology and Pathophysiology, School of Basic Medicine, He’nan University of Chinese Medicine, He’nan Province, Zhengzhou 450046, China |
|
|
|
Abstract Objective To investigate the molecular mechanism of Yiqi Huatan Prescription in the treatment of coronavirus disease 2019 (COVID-19) by network pharmacology. Methods The active ingredients and potential targets in Yiqi Huatan Prescription were searched by traditional Chinese medicine systems pharmacology database and analysis platform. The drug-ingredient-target network was established. GeneCards database was used to screen the related targets of COVID-19, and STRING database was used to analyze the protein-protein interaction of the common targets of COVID-19 and drug action. Gene ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed using DAVID database. Results A total of 145 active ingredients, 267 potential action targets were screened from Yiqi Huatan Prescription, and a total of 251 COVID-19 related targets were screened, 56 targets were obtained through the intersection between the ingredient-target and COVID-19 related targets, and ten key targets were identified after topological analysis. GO analysis showed that Yiqi Huatan Prescription was involved in 57 biological processes, 11 molecular functions and four cellular components, such as inflammation response, immune response, apoptosis process, positive and negative regulation of apoptosis process, proteins binding, enzymes binding, cytokine activity and so on. KEGG analysis obtained 25 pathways including some infectious diseases such as Chagas disease, hepatitis B, pulmonary tuberculosis and pertussis as well as some signaling pathways such as tumor necrosis factor signaling pathway, Toll-like receptor signaling pathway, and mitogen-activated protein kinase signaling pathway. Conclusion Yiqi Huatan Prescription may have potential therapeutic effect against COVID-19 through synergy of multi-functions, multi-targets and multi-pathways, provides theoretical support and scientific basis for traditional Chinese medicine matching further study and clinical application.
|
|
|
|
|
|
[1] 崔琳琳，宋亚刚，苗明三.基于网络药理学和分子对接的陈皮干预COVID-19的可能机制[J/OL].中药药理与临床：1-17[2020-08-06].https：//doi.org/10.13412/j.cnki.zyyl. 20200630.003.
[2] 蔡孟成，俞超芹.基于网络药理学的金振口服液干预新冠肺炎的机制研究[J].药学实践杂志，2020，38（3）：193-201.
[3] 董陈颍，杨鸿.基于网络药理学探讨宣白承气汤对新冠肺炎的抗炎作用机制[J/OL].海南医学院学报：1-13[2020-08-07].https：//doi.org/10.13210/j.cnki.jhmu.20200730.002.
[4] Russell CD，Millar JE，Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury [J]. Lancet，2020，395（10223）：473-475.
[5] 国家中医药管理局.新型冠状病毒肺炎诊疗方案（试行第七版）中医方案部分（第一部分）[J].实用中医内科杂志，2020，34（4）：4.
[6] 李春梅，张治.益气宣肺汤加减治疗慢性阻塞性肺疾病稳定期肺脾气虚型患者对肺功能及血清学指标的影响[J].世界中西医结合杂志，2020，15（11）：2067-2071.
[7] 国家卫生健康委.新型冠状病毒肺炎诊疗方案（试行第八版）[EB/OL]. [2020-12-18]. http：//www. nhc. gov. cn/cms-search/downFiles/a449a3e2e2c94d9a856d5faea2ff0f94.
[8] 刘施吟，胡渊龙，陈宪海.神术散治疗新型冠状病毒肺炎的分子机制研究[J/OL].中药材，2020（4）：1041-1046[2020-08-11].https：//doi.org/10.13863/j.issn1001-4454. 2020.04.048.
[9] 李婧，马小兵，沈杰，等.基于文献挖掘与分子对接技术的抗新型冠状病毒中药活性成分筛选[J].中草药，2020， 51（4）：845-850.
[10] 宗阳，丁美林，贾可可，等.基于网络药理学和分子对接法探寻达原饮治疗新型冠状病毒肺炎（COVID-19）活性化合物的研究[J].中草药，2020，51（4）：836-844.
[11] 孙凯滨，张新雨，刘静，等.小柴胡汤治疗早期新型冠状病毒肺炎（COVID-19）邪热郁肺、枢机不利证功效网络分析与机制预测[J].中草药，2020，51（7）：1750-1760.
[12] 程若东.基于网络药理学的“固本通络汤”治疗慢性萎缩性胃炎的作用机制研究[D].北京：中国中医科学院，2019.
[13] 左军，牟景光，胡晓阳.半夏化学成分及现代药理作用研究进展[J].辽宁中医药大学学报，2019，21（9）：26-29.
[14] 李冀，李想，曹明明，等.甘草药理作用及药对配伍比例研究进展[J].上海中医药杂志，2019，53（7）：83-87.
[15] 顾思浩，孔维崧，张彤，等.白术的化学成分与药理作用及复方临床应用进展[J].中华中医药学刊，2020，38（1）：69-73.
[16] 朱天碧，张钊，罗飘，等.党参药理学作用的相关研究进展[J].神经药理学报，2018，8（6）：46.
[17] 马传贵，张志秀.茯苓的中医药研究现状与临床治疗进展[J].食用菌，2020，42（4）：4-8.
[18] 王艳慧.化橘红的研究进展[J].世界科学技术-中医药现代化，2017，19（6）：1076-1082.
[19] 张红，孙明江，王凌.枳实的化学成分及药理作用研究进展[J].中药材，2009，32（11）：1787-1790.
[20] Vilahur G，Ben-Aicha S，Diaz-Riera E，et al. Phytosterols and Inflammation [J]. Curr Med Chem，2019，26（37）：6724-6734.
[21] 张帆.植物甾醇的生物活性与构效关系初探[D].南昌：南昌大学，2018.
[22] 肖涵，张莉，王露，等.柚皮素可抑制磷酸化蛋白激酶C-δ改善大鼠脑出血后炎症损伤[J].第三军医大学学报，2020，42（10）：981-988.
[23] Frabasile S，Koishi AC，Kuczera D，et al. The citrus flavanone naringenin impairs dengue virus replication in human cells[J]. Scientific Reports，2017，7：41864.
[24] 赵晶晶.中药有效成分抗豚鼠巨细胞病毒体外实验研究[D].武汉：华中科技大学，2011.
[25] 李贝金，李潇，薛嘉睿，等.新冠肺炎炎症风暴的机制探讨及中医药的干预作用[J].中国实验方剂学杂志，2020， 26（13）：32-38.
[26] Holbrook J，Lara-Reyna S，Jarosz-Griffiths H，et al. Tumour necrosis factor signaling in health and disease [J]. F1000Research，2019，8：F1000.
[27] 鄢海燕，邹纯才.含瓜蒌方剂的组方规律及核心药对“瓜蒌-甘草”的作用机制：基于网络药理学和分子对接技术[J].南方医科大学学报，2021，41（2）：173-183.
[28] 程海飞，陈艳琳，范绍辉，等.MAPK信号通路在急性肺损伤进程中的研究进展[J].医学综述，2020，26（13）：2523-2528.
[29] Huang C，Wang Y，Li X，et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan，China [J]. Lancet，2020，395（10223）：497-506.
[30] Tanaka T，Narazaki M，Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm [J]. Immunotherapy，2016，8（8）：959-970.
[31] 宗阳，姚卫峰，居文政.以白介素6为受体挖掘中药单体治疗新型冠状病毒肺炎引发的细胞因子风暴的干预作用[J].中国医院药学杂志，2020，40（11）：1182-1188.
[32] Yu D，Ma C，Yue Z，et al. Protective effect of naringenin against lipopolysaccharide-induced injury in normal human bronchial epithelium via suppression of MAPK signaling [J]. Inflammation，2015，38（1）：195-204.
[33] Rungsung S，Singh TU，Rabha DJ，et al. Luteolin attenuates acute lung injury in experimental mouse model of sepsis [J]. Cytokine，2018，110：333-343. |
|
|
|
